Brief: Sonnet Biotherapeutics Reports Data From Phase 1b/2a Clinical Trial Of SON-080

Sonnet Biotherapeutics Holdings

24/07/2024 13:38

July 24 (Reuters) - Sonnet Biotherapeutics Holdings Inc
 SONN.O :
    * SONNET BIOTHERAPEUTICS REPORTS ENCOURAGING DATA FROM PHASE
1B/2A
CLINICAL TRIAL OF SON-080 IN CHEMOTHERAPY-INDUCED PERIPHERAL
NEUROPATHY (CIPN) THAT SUPPORT ADVANCEMENT INTO PHASE 2 STUDY
    * SONNET BIOTHERAPEUTICS HOLDINGS INC - SON-080
WELL-TOLERATED AT
BOTH DOSES

Source text for Eikon:  ID:nGNX426X9S 
Further company coverage:  SONN.O 

 ((Reuters.Briefs@thomsonreuters.com;))